Merck unit sues India's Glenmark over diabetes drug

MUMBAI, April 2 Tue Apr 2, 2013 8:40pm IST

Related Topics

Stocks

   

MUMBAI, April 2 (Reuters) - A unit of U.S. drugmaker Merck & Co sued India's Glenmark Pharmaceuticals on Tuesday for infringing its patent on two diabetes drugs.

The action comes a day after Swiss drugmaker Novartis AG lost a landmark court ruling over patent protection for its cancer treatment Glivec, a decision widely seen as boosting India's generic pharmaceuticals business.

Merck's Indian unit, MSD, holds an Indian patent on sitagliptin, a chemical compound sold under the Januvia and Janumet brands.

Although the patent is yet to expire, Mumbai-based Glenmark confirmed it had launched generic versions of the two drugs.

"Glenmark is a responsible company and has launched the products after due diligence and research," it said in an emailed statement.

MSD filed its case with the Delhi High Court on Tuesday, saying it was disappointed with Glenmark's decision to launch products that directly infringed its intellectual property.

There are about 65 million patients in India being treated for type 2 diabetes, MSD said.

"We believe our patents for Januvia and Janumet are valid and enforceable and will vigorously defend them," MSD said in an email to Reuters.

Januvia costs nearly 1,300 rupees ($23.92) for a month's dose while Glenmark has offered the drug at a discount of about 30 percent, an industry source said.

Neither company would comment on their prices.

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

Sino-Indian Ties

REUTERS SHOWCASE

India-China Relations

India-China Relations

India and China look to put knotty relations on new footing.  Full Article 

Importing Iron Ore

Importing Iron Ore

As mining curbs bite, India offers market to glut-hit iron ore.  Full Article 

Lower Output

Lower Output

IOC cuts refinery output as rains hit fuel demand - source.  Full Article 

Drug Approval

Drug Approval

Epirus, Ranbaxy win India approval for arthritis drug copy.  Full Article 

Farming and Technology

Farming and Technology

Climate smart farmers get tech savvy to save India's bread basket.  Full Article 

Rajan Speaks

Rajan Speaks

RBI chief Rajan says limiting reliance on foreign debt.  Full Article 

India-Vietnam Ties

India-Vietnam Ties

India tightens Vietnam defence, oil ties ahead of China Xi's visit.  Full Article 

Debt & Equity Deal

Debt & Equity Deal

KKR to lend $175 million to GMR Infrastructure - source.  Full Article 

Preparing for IPO

Preparing for IPO

Alibaba boosts IPO as demand strengthens.  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage